The Transformation of U.S. Livestock Agriculture: Scale, Efficiency, and Risks

U.S. livestock production has shifted to much larger and more specialized farms, and the various stages of input provision, farm production, and processing are now much more tightly coordinated through formal contracts and shared ownership of assets. Important financial advantages have driven these structural changes, which in turn have boosted productivity growth in the livestock sector. But structural changes can also generate environmental and health risks for society, as industrialization concentrates animals and animal wastes in localized areas. This report relies on farm-level data to detail the nature, causes, and effects of structural changes in livestock production.Livestock, dairy, broilers, hogs, fed cattle, farm structure, scale economies, contract agriculture, CAFOs, growth-promoting antibiotics, Farm Management, Livestock Production/Industries,

Seasonal Variation in 25(OH)D at Aberdeen (57°N) and Bone Health Indicators- Could Holidays in the Sun and Cod Liver Oil Supplements Alleviate Deficiency?

Vitamin D has been linked with many health outcomes. The aim of this longitudinal study, was to assess predictors of seasonal variation of 25-hydroxy-vitamin D (25(OH)D) (including use of supplements and holidays in sunny destinations) at a northerly latitude in the UK (57°N) in relation to bone health indicators. 365 healthy postmenopausal women (mean age 62.0 y (SD 1.4)) had 25(OH)D measurements by immunoassay, serum C-telopeptide (CTX), estimates of sunlight exposure (badges of polysulphone film), information regarding holidays in sunny destinations, and diet (from food diaries, including use of supplements such as cod liver oil (CLO)) at fixed 3-monthly intervals over 15 months (subject retention 88%) with an additional 25(OH)D assessment in spring 2008. Bone mineral density (BMD) at the lumbar spine (LS) and dual hip was measured in autumn 2006 and spring 2007 (Lunar I-DXA). Deficiency prevalence (25(OH)

Effect of strobilurin fungicides on control of early blight (Alternaria solani) and yield of potatoes grown under two N fertility regimes

Early blight, caused by Alternaria solani, is a ubiquitous disease that can reduce potato yield. Adequate crop fertility and appropriate fungicide applications usually suppress the development of this disease. Field trials were established in Prince Edward Island to determine whether strobilurin analogs, namely azoxystrobin and pyraclostrobin, could suppress early blight of potatoes (cvs. Shepody and Russet Burbank) grown under two nitrogen (N) fertility regimes (high or low N). Azoxystrobin and pyraclostrobin were linked to significantly higher total tuber yield for Russet Burbank in 2003 and Shepody in 2004 when compared to plots receiving no strobilurin fungicides. No significant differences in total tuber yield based on N fertility were observed, although the high N rate decreased disease in Russet Burbank control plots in 2004. Due to an absence of early blight in 2003, the increase in Russet Burbank yield may be attributed to the physiological and developmental alterations brought about by strobilurin products in treated plants. In 2004, early blight was severe in inoculated control plots, but it was significantly suppressed in plots having received azoxystrobin or pyraclostrobin, regardless of the cultivar type or fertility regime. Therefore, to prevent unnecessary N inputs, growers need to supply only the necessary N amount to optimize tuber yields and manage early blight with fungicides.L’alternariose, causée par Alternaria solani, est une maladie omniprésente qui peut réduire le rendement de la pomme de terre. Une fertilisation adéquate de la culture et l’application de fongicides appropriés suppriment généralement le développement de cette maladie. Des essais en champs ont été effectués à l’Île-du-Prince-Édouard pour déterminer si des analogues de la strobilurine, notamment l’azoxystrobine et la pyraclostrobine, pouvaient supprimer l’alternariose de la pomme de terre (cv. Shepody et Russet Burbank) cultivée sous deux régimes de fertilité azotée (forte et faible doses de N). L’azoxystrobine et la pyraclostrobine ont été associées au rendement total en tubercules significativement supérieur pour Russet Burbank en 2003 et pour Shepody en 2004, comparativement à des parcelles n’ayant reçu aucun fongicide apparenté à la strobilurine. La fertilité azotée n’a entraîné aucune différence significative du rendement, bien que la dose élevée d’azote ait significativement réduit la maladie dans les parcelles témoins de Russet Burbank en 2004. En raison de l’absence de l’alternariose en 2003, l’augmentation du rendement du cv. Russet Burbank peut être attribuée aux modifications causées par les produits de la strobilurine dans la physiologie et le développement des plantes traitées. En 2004, l’alternariose a été importante dans les parcelles témoins inoculées, mais la suppression a été significative dans les parcelles ayant reçu de l’azoxystrobine ou de la pyraclostrobine, quels que soient le cultivar ou le régime de fertilité. Ainsi, les producteurs devraient appliquer uniquement les quantités d’azote nécessaires pour optimiser les rendements en tubercules et contrôler l’alternariose avec des fongicides

Profits, Costs, and the Changing Structure of Dairy Farming

U.S. dairy production is consolidating into fewer but larger farms. This report uses data from several USDA surveys to detail that consolidation and to analyze the financial drivers of consolidation. Specifically, larger farms realize lower production costs. Although small dairy farms realize higher revenue per hundredweight of milk sold, the cost advantages of larger size allow large farms to be profitable, on average, even while most small farms are unable to earn enough to replace their capital. Further survey evidence, as well as the financial data, suggest that consolidation is likely to continue.Dairy farming, economies of scale, economies of size, dairy farm structure, milk costs, Farm Management, Industrial Organization, Livestock Production/Industries,

A novel tool to measure extracellular glutamate in the Zebrafish nervous system in vivo

Glutamate is the major excitatory neurotransmitter in the brain. Its release and eventual recycling are key to rapid sustained neural activity. We have paired the gfap promoter region with the glutamate reporter molecule, iGluSnFR, to drive expression in glial cells throughout the nervous system. Tg(gfap:iGluSnFR) is expressed on the glial membrane of Müller glia cells in the retina, which rapidly respond to stimulation and the release of extracellular glutamate. As glial cells are associated with most, if not all, synapses, Tg(gfap:iGluSnFR) is a novel and exciting tool to measure neuronal activity and extracellular glutamate dynamics in many regions of the nervous system. Glutamate is the major excitatory neurotransmitter in the brain. Its release and eventual recycling are key to rapid sustained neural activity.1 Glial cells play a key role in the uptake and recycling of glutamate from the synaptic cleft. iGluSnFR has been used to study synaptic activity by measuring glutamate dynamics in the zebrafish nervous system.2,3 Previous work has also used iGluSnFR in glial cells; however, this was done transiently in the mouse using viral vectors.2,4 As such, we designed a transgene to stably express iGluSnFR in the glial cells of the zebrafish nervous system. We report a novel transgenic zebrafish, Tg(gfap:iGluSnFR), that displays the glutamate-sensitive fluorescent reporter iGluSnFR specifically on the membrane of glial cells (Figure 1A–C). This molecule is expressed on the glial membrane in many brain regions and rapidly responds to stimulation and the release of extracellular glutamate (Figure 1D–F, Supplementary Data; Supplementary Data are available online at www.liebertpub.com/zeb). Thus, pairing the sensitivity of iGluSnFR and optical transparency of the zebrafish provides a powerful tool for understanding glutamate dynamics in neural tissues in vivo

Concealed anterograde accessory pathway conduction during the induction of orthodromic reciprocating tachycardia

AbstractThe purpose of this study was to determine whether concealed anterograde accessory pathway conduction occurs during the induction of orthodromic tachycardia by an artrial extrastimulus (S2). Sixteen patients with an overt (n = 9) or concealed (n = 7) accessory pathway had inducible orthodromic tachycardia by S2during an atrial drive (S1) cycle length of 500 to 650 ms. A ventricular extrastimulus (S3) was introduced coincident with the His depolarization resulting from S2during the longest S1S2interval that reproducibly induced orthodromic tachycardia. The S1S3interval was decreased in 10 ms steps until S3reached ventricular refractoriness. Retrograde accessory pathway conduction of S3in the presence and absence of S2was compared at the same S1S3intervals.In the absence of S2there was retrograde accessory pathway conduction after S3in each patient. In the presence of S2, in patients with overt pre-excitation, retrograde accessory pathway conduction after S3was absent in one patient, prolonged in four patients and present only after long S1S3intervals in three patients. Only one patient had unchanged retrograde conduction regardless of the presence or absence of S2. In patients with a concealed accessory pathway, retrograde accessory pathway conduction after S3was absent in five patients and was prolonged in two. Thus, concealed anterograde accessory pathway conduction was present in 15 of 16 patients at the time of orthodromic tachycardia induction.In conclusion, concealed anterograde accessory pathway conduction occurs in a majority of patients with an overt or a concealed accessory pathway during induction of orthodromic tachycardia by an atrial extrastimulus. In some patients, the initiation of orthodromic tachycardia may depend on a critical interaction between the degree of concealed anterograde accessory pathway conduction and atrioventricular conduction delay after S2

Effect of vitamin D supplementation on blood pressure:a systematic review and meta-analysis incorporating individual patient data

D-PRESSURE Collaboration: et al.[Importance]: Low levels of vitamin D are associated with elevated blood pressure (BP) and future cardiovascular events. Whether vitamin D supplementation reduces BP and which patient characteristics predict a response remain unclear.[Objective]: To systematically review whether supplementation with vitamin D or its analogues reduce BP.[Data Sources]: We searched MEDLINE, CINAHL, EMBASE, Cochrane Central Register of Controlled Trials, and http://www.ClinicalTrials.com augmented by a hand search of references from the included articles and previous reviews. Google was searched for gray literature (ie, material not published in recognized scientific journals). No language restrictions were applied. The search period spanned January 1, 1966, through March 31, 2014.[Study Selection]: We included randomized placebo-controlled clinical trials that used vitamin D supplementation for a minimum of 4 weeks for any indication and reported BP data. Studies were included if they used active or inactive forms of vitamin D or vitamin D analogues. Cointerventions were permitted if identical in all treatment arms.[Data Extraction and Synthesis]: We extracted data on baseline demographics, 25-hydroxyvitamin D levels, systolic and diastolic BP (SBP and DBP), and change in BP from baseline to the final follow-up. Individual patient data on age, sex, medication use, diabetes mellitus, baseline and follow-up BP, and 25-hydroxyvitamin D levels were requested from the authors of the included studies. For trial-level data, between-group differences in BP change were combined in a random-effects model. For individual patient data, between-group differences in BP at the final follow up, adjusted for baseline BP, were calculated before combining in a random-effects model.[Main Outcomes and Measures]: Difference in SBP and DBP measured in an office setting.[Results]: We included 46 trials (4541 participants) in the trial-level meta-analysis. Individual patient data were obtained for 27 trials (3092 participants). At the trial level, no effect of vitamin D supplementation was seen on SBP (effect size, 0.0 [95% CI, −0.8 to 0.8] mm Hg; P = .97; I2 = 21%) or DBP (effect size, −0.1 [95% CI, −0.6 to 0.5] mm Hg; P = .84; I2 = 20%). Similar results were found analyzing individual patient data for SBP (effect size, −0.5 [95% CI, −1.3 to 0.4] mm Hg; P = .27; I2 = 0%) and DBP (effect size, 0.2 [95% CI, −0.3 to 0.7] mm Hg; P = .38; I2 = 0%). Subgroup analysis did not reveal any baseline factor predictive of a better response to therapy.[Conclusions and Relevance]: Vitamin D supplementation is ineffective as an agent for lowering BP and thus should not be used as an antihypertensive agent.Peer reviewe

Clinical evidence for overcoming capecitabine resistance in a woman with breast cancer terminating in radiologically occult micronodular pseudo-cirrhosis with portal hypertension: a case report

<p>Abstract</p> <p>Introduction</p> <p>We report a case of stage IV breast cancer terminating in an unusual picture of radiologically occult micronodular pseudo-cirrhosis. Contrast-enhanced computed tomography showed no evidence of metastatic breast cancer within the liver. Unlike the few previously reported cases of intrasinusoidal spread of breast cancer, our patient was palliated with a transjugular intrahepatic portosystemic shunt along with salvage chemohormonal therapy. In addition, our patient demonstrated proof of the principle of the dependence of capecitabine (Xeloda) efficacy on dose scheduling as predicted by laboratory studies based on Gompertzian tumor growth and the Norton-Simon hypothesis.</p> <p>Case presentation</p> <p>We report the case of a 52-year-old Caucasian woman who developed radiological signs of portal hypertension without radiological evidence of hepatic metastasis five years after being diagnosed with metastatic breast cancer. She was receiving chemotherapy for stage IV breast cancer initially thought to be metastatic only to the bones. During salvage therapy with high-dose estradiol (Estradiol valerate), vinorelbine (Navelbine) and bevacizumab (Avastin), she suddenly developed signs of portal hypertension confirmed on computed tomography and by portal and systemic venous pressure measurements. Drug toxicity due to bevacizumab (Avastin) was initially and incorrectly entertained as a cause. The patient underwent palliative transjugular intrahepatic portosystemic shunt and transhepatic venous liver biopsy, which revealed the presence of rapidly progressive and uncontrolled metastatic breast cancer. The new discovery of radiologically occult intrasinusodal hepatic metastases with secondary micronodular cirrhosis was found to be the cause of her sudden onset portal hypertension. The patient's resistance to capecitabine (Xeloda) was reversed by changing the schedule of medication to biweekly 7/7 (7 days ingesting drug alternating with 7 days off drug) from the 14/7 (14 days ingesting drug alternating with a 7 day rest period) day schedule approved by the US Food and Drug Administration.</p> <p>Conclusion</p> <p>This case report demonstrates an unusual presentation of radiographically occult hepatic metastasis from breast cancer palliated with transjugular intrahepatic portosystemic shunt. All patients with advanced breast cancer developing unexpected portal hypertension should be considered candidates for liver biopsy despite normal computed tomography of the liver imaging results. This is the first report of a reversal of clinical resistance to capecitabine (Xeloda) by changing from the schedule of 14/7 day to a biweekly 7/7 day schedule. This suggests that a biweekly schedule may be best for some patients.</p